JP2018521000A - Ｄ２ｏで安定化された医薬製剤 - Google Patents

Ｄ２ｏで安定化された医薬製剤 Download PDF

Info

Publication number
JP2018521000A
JP2018521000A JP2017559857A JP2017559857A JP2018521000A JP 2018521000 A JP2018521000 A JP 2018521000A JP 2017559857 A JP2017559857 A JP 2017559857A JP 2017559857 A JP2017559857 A JP 2017559857A JP 2018521000 A JP2018521000 A JP 2018521000A
Authority
JP
Japan
Prior art keywords
ophthalmic
composition
less
months
ophthalmic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017559857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521000A5 (enExample
Inventor
アイ． オストロー，グレゴリー
アイ． オストロー，グレゴリー
ジェイ． ウィダー，ケネス
ジェイ． ウィダー，ケネス
エス． ベイカー，デビッド
エス． ベイカー，デビッド
Original Assignee
シドネキシス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シドネキシス，インク． filed Critical シドネキシス，インク．
Publication of JP2018521000A publication Critical patent/JP2018521000A/ja
Publication of JP2018521000A5 publication Critical patent/JP2018521000A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017559857A 2015-05-29 2016-05-27 Ｄ２ｏで安定化された医薬製剤 Pending JP2018521000A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168538P 2015-05-29 2015-05-29
US62/168,538 2015-05-29
PCT/US2016/034823 WO2016196367A1 (en) 2015-05-29 2016-05-27 D2o stabilized pharmaceutical formulations

Publications (2)

Publication Number Publication Date
JP2018521000A true JP2018521000A (ja) 2018-08-02
JP2018521000A5 JP2018521000A5 (enExample) 2019-07-04

Family

ID=57442106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017559857A Pending JP2018521000A (ja) 2015-05-29 2016-05-27 Ｄ２ｏで安定化された医薬製剤

Country Status (6)

Country Link
US (5) US11052094B2 (enExample)
EP (1) EP3302426A4 (enExample)
JP (1) JP2018521000A (enExample)
CN (2) CN118453493A (enExample)
HK (1) HK1248570A1 (enExample)
WO (1) WO2016196367A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023011818A (ja) * 2020-12-24 2023-01-24 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP2023518853A (ja) * 2020-03-25 2023-05-08 アウフバウ・メディカル・イノベイションズ・リミテッド 緑内障のためのプロセスおよび薬剤
JP2024510876A (ja) * 2021-03-22 2024-03-12 アイクロム エスアールエル インドシアニングリーン及びフルオレセインナトリウムの固体組成物
WO2025004579A1 (ja) * 2023-06-30 2025-01-02 株式会社ニデック 眼科用組成物

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
PT3548091T (pt) 2016-11-29 2022-01-21 Oculis SA Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo
WO2018193367A1 (en) * 2017-04-19 2018-10-25 Zenvision Pharma Llp Novel pharmaceutical composition comprising combination of alcaftadine and nepafenac along with antibacterial and/or antiviral an/or antifungal drug
KR102643190B1 (ko) 2017-06-10 2024-03-04 아이노비아 인코포레이티드 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들
CN109706238B (zh) 2017-10-26 2023-04-07 珠海岐微生物科技有限公司 一种老年性黄斑病变的检测与治疗方法
US10293047B1 (en) 2017-11-15 2019-05-21 Paragon BioTeck, Inc. Fluorescein and benoxinate compositions
EP3713530A4 (en) * 2017-11-21 2021-08-18 Sydnexis, Inc. OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT
US20190209471A1 (en) * 2018-01-11 2019-07-11 Panaseea, LLC Buffered compositions and methods for their use in surface treatments
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼の状態の治療のためのピロカルピン塩酸塩の使用
EP3814492A4 (en) * 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020014426A1 (en) * 2018-07-11 2020-01-16 Parenteral Technologies, Llc Highly concentrated formulations and methods for producing large batch pharmaceutical formulations
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
US20210369648A1 (en) * 2018-10-06 2021-12-02 Biotheravision Llc Cysteamine zinc complex and method of using a cysteamine zinc complex
IL283127B2 (en) 2018-11-14 2026-06-01 Smilebiotek Zhuhai Ltd Animal models, screening methods, and treatment methods for intraocular diseases or disorders
CN109674758A (zh) * 2019-02-25 2019-04-26 湖南博隽生物医药有限公司 一种用于治疗癫痫的双丙戊酸钠缓释片及其制备方法
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
US11071724B2 (en) * 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021001366A1 (en) 2019-07-01 2021-01-07 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
US20230285350A1 (en) * 2020-07-15 2023-09-14 Lyotip, Inc. Formulations for tetracaine and lidocaine
WO2022092868A1 (ko) * 2020-10-29 2022-05-05 주식회사태준제약 안과용 조성물
CN116648485B (zh) * 2020-12-03 2025-08-29 贝克曼库尔特有限公司 用于稳定的台盼蓝溶液的组合物和方法
EP4262809A4 (en) * 2020-12-17 2024-10-23 Harrow IP, LLC MYDRIATIC COMPOSITIONS AND METHODS OF MANUFACTURE THEREOF
WO2022159813A1 (en) * 2021-01-25 2022-07-28 Lennham Pharmaceuticals, Inc. Products comprising deuterium-enriched water
US11872213B2 (en) * 2021-01-28 2024-01-16 Glaukos Corporation Formulations
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
WO2022235371A1 (en) 2021-05-04 2022-11-10 University Of Notre Dame Du Lac Deuterated indole heptamethine cyanine dyes
US20230039551A1 (en) 2021-07-23 2023-02-09 Somerset Therapeutics, Llc Buffer- and chelator-free, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US12029729B2 (en) 2021-07-23 2024-07-09 Somerset Therapeutics, Llc Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
US20230277694A1 (en) * 2022-03-04 2023-09-07 Harrow Ip, Llc Ophthalmic dye composition and method for administering same
KR20250092172A (ko) * 2022-09-01 2025-06-23 옵티파이 테라퓨틱스 아게 안과용 조성물
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
IL322056A (en) * 2023-03-18 2025-09-01 Alcon Inc Pharmaceutical preparations containing apreclonidine to relieve eye redness
WO2026128000A1 (en) * 2024-12-12 2026-06-18 Iview Therapeutics, Inc. Gel forming ophthalmic compositions containing povidone iodine and steroids

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (enExample) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
WO1997016192A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
CA2250780A1 (en) 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (enExample) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
CA2374003C (en) 1999-05-17 2008-02-12 Aesgen, Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
JP5000835B2 (ja) 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CN1509172A (zh) 2001-05-25 2004-06-30 ά����ҩ��˾ 哌仑西平眼用凝胶剂
JP2003063576A (ja) 2001-06-15 2003-03-05 Taisei Kako Co Ltd 分与容器
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
MXPA06001776A (es) 2003-08-15 2007-09-07 Qlt Usa Inc Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo.
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2005072656A1 (en) 2004-01-27 2005-08-11 Osteotech, Inc. Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
MX2007009417A (es) 2005-02-04 2007-08-17 Univ Auburn Sistema de suministro de farmaco de contacto.
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
WO2007053747A2 (en) 2005-11-01 2007-05-10 President And Fellows Of Harvard College Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
CA2702082A1 (en) 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
ES2459198T3 (es) 2008-04-20 2014-05-08 D2 Bioscience Group Ltd Utilización de óxido de deuterio como inhibidor de elastasa
EP2962682B1 (en) 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
US8883214B2 (en) 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
US20120203161A1 (en) 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US8945101B2 (en) 2010-04-30 2015-02-03 Seros Medical, Llc Method and apparatus for treatment of ocular tissue using combine modalities
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
MX2013000604A (es) 2010-07-15 2013-07-05 Corinthian Ophthalmic Inc Suministro oftálmico de fármaco.
AU2011278934B2 (en) 2010-07-15 2015-02-26 Eyenovia, Inc. Drop generating device
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
US8530449B2 (en) 2010-09-09 2013-09-10 Assad S. Sawaya Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
EP2675455A4 (en) 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
JP2014506936A (ja) 2011-03-03 2014-03-20 アラーガン インコーポレイテッド シリコーンベースの眼科製剤
EP2694048B1 (en) 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
MX360666B (es) * 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
US20140350049A1 (en) 2011-11-29 2014-11-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
AU2013245946A1 (en) 2012-04-10 2014-11-27 Eyenovia, Inc. Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
BR112014028069A2 (pt) 2012-05-11 2017-08-08 Cipla Ltd composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
IN2014DN10521A (enExample) 2012-05-14 2015-08-21 Corinthian Ophthalmic Inc
SG11201407431RA (en) 2012-05-15 2014-12-30 Eyenovia Inc Ejector devices, methods, drivers, and circuits therefor
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
WO2014161002A2 (en) 2013-03-29 2014-10-02 Onefocus Technology, Llc Drug delivery from contact lenses with a fluidic module
WO2014182620A1 (en) 2013-05-06 2014-11-13 Kaohsiung Chang Gung Memorial Hospital Pharmaceutical composition and uses thereof
CR20190156A (es) * 2013-05-17 2019-05-16 Incyte Corp Derivados de bipirazol como inhibidores jak
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016025560A1 (en) 2014-08-13 2016-02-18 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20210267885A1 (en) 2016-05-25 2021-09-02 Singapore Health Services Ptel Ltd Atropine-containing aqueous composition
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
KR102472774B1 (ko) 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
EP3585386A4 (en) 2017-02-21 2020-12-30 Singapore Health Services PTE Ltd COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE
EP3970694A1 (en) 2017-05-11 2022-03-23 Vyluma Inc. Atropine pharmaceutical compositions
EP3654964B1 (en) 2017-07-20 2024-04-24 Seinda Pharmaceutical Guangzhou Corporation Composition comprising atropine and a miotic agent and its use in the treatment of myopia
EP3713530A4 (en) 2017-11-21 2021-08-18 Sydnexis, Inc. OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
JP2023505841A (ja) 2019-12-16 2023-02-13 シドネキシス，インク． Ｄ２ｏを含む眼科用組成物
US20240139166A1 (en) 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ISOTOPES IN ENVIROMENTAL AND HEALTH STUDIES, vol. 47, no. 1, JPN6020007925, 2011, pages 1 - 17, ISSN: 0004411004 *
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 51, no. 12, JPN6020007924, 1962, pages 1166 - 1169, ISSN: 0004411003 *
大橋裕一, 眼科 NEW INSIGHT 第2巻 点眼薬−常識と非常識−, JPN6020007926, 10 July 1997 (1997-07-10), pages 9 - 14, ISSN: 0004411005 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518853A (ja) * 2020-03-25 2023-05-08 アウフバウ・メディカル・イノベイションズ・リミテッド 緑内障のためのプロセスおよび薬剤
JP2023011818A (ja) * 2020-12-24 2023-01-24 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP7858506B2 (ja) 2020-12-24 2026-05-14 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP2024510876A (ja) * 2021-03-22 2024-03-12 アイクロム エスアールエル インドシアニングリーン及びフルオレセインナトリウムの固体組成物
JP7872795B2 (ja) 2021-03-22 2026-06-10 アイクロム エスアールエル インドシアニングリーン及びフルオレセインナトリウムの固体組成物
WO2025004579A1 (ja) * 2023-06-30 2025-01-02 株式会社ニデック 眼科用組成物

Also Published As

Publication number Publication date
US11052095B2 (en) 2021-07-06
US20210283142A1 (en) 2021-09-16
US11052094B2 (en) 2021-07-06
EP3302426A1 (en) 2018-04-11
US20250275983A1 (en) 2025-09-04
US20200197410A1 (en) 2020-06-25
HK1248570A1 (zh) 2018-10-19
CN118453493A (zh) 2024-08-09
WO2016196367A1 (en) 2016-12-08
US12168017B2 (en) 2024-12-17
CN107847432A (zh) 2018-03-27
EP3302426A4 (en) 2018-12-05
US12070466B2 (en) 2024-08-27
US20210393649A1 (en) 2021-12-23
US20180147214A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
US20250275983A1 (en) D2o stabilized pharmaceutical formulations
US20250186251A1 (en) Ophthalmic composition and delivery device thereof
US11883390B2 (en) Ophthalmic composition
US20240139166A1 (en) Ophthalmic compositions for presbyopia
US20230041788A1 (en) Ophthalmic compositions comprising d2o
HK40082459A (en) Ophthalmic compositions comprising d2o

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201221